Buserelin

ApprovedSmall molecule

NNCIC Clinical Trials Group

Buserelin is one of 101 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaActive, not recruiting

Ovarian ReserveActive, not recruiting

Prostate CancerActive, not recruiting

Prostate AdenocarcinomaPhase 3

Active, not recruiting

Ovarian ReserveApproved

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Buserelin

NNCIC Clinical Trials Group

Approved

4 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Duragesic

CCephalon

Preclinical

1 6

Prednisone/prednisolone

Roche

Preclinical

3 7

Triptorelin Pamoate

Ipsen

Preclinical

2 8

Osmitrol

BB. Braun Medical Inc.

Preclinical

—9

Ifex

BBaxter Healthcare Corporation

Preclinical

—10

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Prostate Adenocarcinoma

NCT05050084

Q4 2033

Phase 3Active, not recruiting

Prostate Adenocarcinoma

NCT04513717

Clinical

Trials by Indication[1]

Prostate Cancer4 trials

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00003653·1,386 enrolled

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00002633·361 enrolled

Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer

Terminated·NNCIC Clinical Trials Group·Phase 3·NCT00651326·48 enrolled

Show 1 more trial

Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

Completed·NNCIC Clinical Trials Group·Phase 1·NCT00054106·25 enrolled

Prostate Adenocarcinoma2 trials

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Active, not recruiting·NNRG Oncology·Phase 3·NCT05050084·2,050 enrolled

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Active, not recruiting·NNRG Oncology·Phase 3·NCT04513717·2,753 enrolled

Ovarian Reserve1 trial

Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles

Terminated·AAndros Day Surgery Clinic·Phase 4·NCT01816789·194 enrolled

Frozen Embryo Transfer1 trial

Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification

Unknown status·YYazd Research & Clinical Center for Infertility·Phase 1/2·NCT00823121·500 enrolled

Flare up1 trial

Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare up Protocol in Poor Responders

Completed·—·Phase 4·NCT01213147·159 enrolled

1 more indication

Unspecified1 trial

Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist

Completed·YYazd Research & Clinical Center for Infertility·Phase 4·NCT00830492·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Buserelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Buserelin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Buserelin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NCIC Clinical Trials Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNCIC Clinical Trials Group

Buserelin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2033

Trials by Indication[1]

Prostate Cancer4 trials

Prostate Adenocarcinoma2 trials

Ovarian Reserve1 trial

Frozen Embryo Transfer1 trial

Flare up1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News